In addition, we will present our perspective on (i) the potential function of the macrophage inhibitory receptor signal regulatory protein alpha (SIRPA or SIRPα) in the homeostasis of tumor-associated macrophages in high-risk neuroblastoma, (ii) how to optimally enhance tumor phagocytosis by macrophages in high-risk neuroblastoma by targeting SIRPA and activating the macrophages, and (iii) recent clinical trials with anti-CD47 antibodies in human adult and pediatric cancers. This evidence concerns the gene CD47 and neuroblastoma.